Stockreport

Looking at the Narrative for OptimizeRx After Guidance Boost and Recurring Revenue Shift [Yahoo! Finance]

OptimizeRx Corporation  (OPRX) 
NASDAQ:AMEX Investor Relations: optimizerx.com/investors
PDF OptimizeRx stock is back in focus after analysts reaffirmed a fair value estimate of about $24.33 per share, even as a slightly higher discount rate reflects a modest up [Read more]